前立腺肥大症におけるTSAA-291の治療成績 - 超音波計測による前立腺の縮小効果を中心として(第2報) -

Abstract

1) Twenty cases with advanced benign prostatic hypertrophy indicated for surgical treatments were administered intramuscularly with 400 mg/week of TSAA-291 for 13 weeks: Among them, 15 cases were closely followed up after the treatment. During the follow-up, their prostatic weights did not change much on measurement using transrectal ultrasonotomography and no rebound effect was recognized. 12 of 15 cases have been kept under satisfactory conditions with symptomatic treatment only for at longest 24 months (average 14 months) after TSAA-291 treatment. Only 3 cases needed surgical treatments up to now among the above 20 cases. The 12 cases will be further followed up, and on relapse TSAA-291 is to be administered again. 2) TSAA-291 was administered intramuscularly 200 mg (1 vial)/week to other 12 cases. Relief of subjective symptoms was obtained in 9 cases (75%), and a decrease of nocturnal frequency in 8 (67%). In 5 (42%), a reductive change was noticed on the prostatic weight. These responses were as good as those to 400 mg (2 vials)/week, though a difference in stage of the disease might be between the cases treated with 400 mg/week and those treated with 200 mg/week. The variety and frequency of side effects were significantly less in the 200 mg/week group than those in the 400 mgjweek one. The clinical improvement mentioned above indicates that a satisfactory therapeutic effect will be obtained in proper cases with 200 mg (1 vial)/week of TSAA-291. It is therefore a question of further studies that only the cases who fail to respond enough to the 200 mg/week treatment, are successively treated with 400 mg/week of TSAA-291.